KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Edwards Lifesciences (EW) Gross Margin (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Gross Margin data on record, last reported at 78.15% in Q4 2025.

  • For Q4 2025, Gross Margin fell 77.0% year-over-year to 78.15%; the TTM value through Dec 2025 reached 78.01%, down 144.0%, while the annual FY2025 figure was 78.01%, 144.0% down from the prior year.
  • Gross Margin reached 78.15% in Q4 2025 per EW's latest filing, roughly flat from 77.77% in the prior quarter.
  • Across five years, Gross Margin topped out at 122.98% in Q4 2022 and bottomed at 75.7% in Q2 2021.
  • Average Gross Margin over 5 years is 80.91%, with a median of 78.78% recorded in 2025.
  • Peak YoY movement for Gross Margin: surged 4626bps in 2022, then tumbled -4280bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 76.72% in 2021, then surged by 60bps to 122.98% in 2022, then plummeted by -35bps to 80.18% in 2023, then fell by -2bps to 78.91% in 2024, then dropped by -1bps to 78.15% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 78.15% in Q4 2025, 77.77% in Q3 2025, and 77.52% in Q2 2025.